Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Alendronate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    51 result(s) found for: Alendronate. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2006-005862-38 Sponsor Protocol Number: Start Date*: 2007-04-05
    Sponsor Name:UCL Mont Godinne
    Full Title: Prevention of Postmenopausal Bone Loss in Osteopenic Women with Alendronate given on a 70 mg Once-every two week Regimen : a 2-year, Double-blind, Placebo-controlled Clinical Trial
    Medical condition: osteopenia and postmenopausal patient
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005040-35 Sponsor Protocol Number: 0120 Start Date*: 2021-01-28
    Sponsor Name:Aarhus University Hospital
    Full Title: The effect of effervescent and buffered alendronate on bone turnover compared to conventional alendronate: A randomized non-inferiority trial
    Medical condition: Osteopenia, i.e. bone mineral density T-score < -1
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10005991 Bone mass decreased LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-003570-11 Sponsor Protocol Number: BC-6072 Start Date*: 2019-10-21
    Sponsor Name:Ghent University Hospital
    Full Title: The use of buffered soluble alendronate 70 mg (Steovess/Binosto) after denosumab discontinuation to prevent increase in bone turnover.
    Medical condition: erosive osteoarthritis of the interphalangeal finger joints
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10016686 Finger osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003924-21 Sponsor Protocol Number: AMP-05/05 Start Date*: 2005-11-15
    Sponsor Name:University of Nottingham
    Full Title: A Randomised, Single-Blind Study to Evaluate Upper Gastrointestinal Handling of Branded versus Generic Alendronate Tablets
    Medical condition: Osteoporosis
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-002255-14 Sponsor Protocol Number: MM17385 Start Date*: 2005-02-01
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Randomized, double-blind, double-dummy, parallel group, multicenter study to compare the efficacy and safety of once-monthly oral administration of 150 mg ibandronate with once-weekly oral administ...
    Medical condition: Study in women with postmenopausal osteoporosis.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) DE (Completed) CZ (Completed) GB (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-002216-10 Sponsor Protocol Number: BA058-05-005 Start Date*: 2012-09-28
    Sponsor Name:Radius Health, Inc.
    Full Title: An Extension Study to Evaluate 24 Months of Standard-of-Care Osteoporosis Management Following Completion of 18 Months of BA058 or Placebo Treatment in Protocol BA058-05-003
    Medical condition: Osteoporosis in postmenopausal women
    Disease: Version SOC Term Classification Code Term Level
    18.1 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: EE (Completed) DK (Completed) CZ (Completed) PL (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003110-27 Sponsor Protocol Number: 21.07.2016 Start Date*: 2016-10-03
    Sponsor Name:Bente Lomholt Langdahl, Dept. of Endocrinology and Internal Medicine, Aarhus University Hospital
    Full Title: Bone turnover markers as predictors of treatment break outcome
    Medical condition: Osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004859 10031289 Osteoporosis, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-003638-28 Sponsor Protocol Number: 2015/576 Start Date*: 2015-09-30
    Sponsor Name:Aarhus University Hospital
    Full Title: ALOSTRA Alendronate treatment of osteoporosis in rheumatoid arthritis – indication and duration. A randomized, doubleblind, placebocontrolled multi-centre study to evaluate the effects of disconti...
    Medical condition: Rheumatoid arthritis and osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10031289 Osteoporosis, unspecified LLT
    20.0 100000004859 10039076 Rheumatoid arthritis and other inflammatory polyarthropathies LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002798-21 Sponsor Protocol Number: 13337 Start Date*: 2018-06-19
    Sponsor Name:University of Oxford
    Full Title: A multi-centre, blinded, randomised, placebo-controlled trial assessing the clinical and cost effectiveness of a 12 month course of oral alendronate (70mg weekly) in patients presenting with avascu...
    Medical condition: Early stage (Ficat 1 or 2), symptomatic, Avascular Necrosis (AVN) of the femoral head
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10005959 Bone disorders (excl congenital and fractures) HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2007-002417-39 Sponsor Protocol Number: ONO-5334POE003 Start Date*: 2007-08-31
    Sponsor Name:Ono Pharmaceutical Co., Ltd.
    Full Title: A MULTI-CENTRE RANDOMISED DOUBLE BLIND, PLACEBO AND ACTIVE CONTROLLED PARALLEL GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ONO-5334 IN POST MENOPAUSAL WOMEN WITH OSTEOPENIA OR OSTEOPOROSIS
    Medical condition: Osteoporosis or Osteopenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049088 Osteopenia LLT
    9.1 10031285 Osteoporosis postmenopausal LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed) LT (Completed) HU (Completed) NL (Completed) EE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2013-001222-26 Sponsor Protocol Number: 2013-1 Start Date*: 2013-08-08
    Sponsor Name:Aalborg University Hospital
    Full Title: Markers of bonestatus in Diabetes Mellitus patients (type 1 and type 2) and the effect of antiresorptive treatment on glycemic markers.
    Medical condition: Diabetes Mellitus and Osteopenia/Osteoporosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-003142-41 Sponsor Protocol Number: 20110142 Start Date*: 2012-03-28
    Sponsor Name:AMGEN INC.
    Full Title: A Multicenter, International, Randomized, Double-blind, Alendronate-controlled Study to Determine the Efficacy and Safety of AMG 785 in the Treatment of Postmenopausal Women With Osteoporosis
    Medical condition: Postmenopausal osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) LT (Completed) FI (Completed) PL (Completed) BE (Completed) CZ (Completed) ES (Completed) EE (Completed) GR (Completed) DE (Completed) GB (Completed) SE (Completed) AT (Completed) DK (Completed) LV (Completed) NO (Completed) NL (Completed) HU (Completed) IE (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-001796-37 Sponsor Protocol Number: ALENDRONATO Start Date*: 2006-06-07
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
    Full Title: Effect of alendronate on spontaneous osteoclastogenesis in postmenopausal osteoporosis
    Medical condition: postmenopausal osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    6.1 10031285 PT
    Population Age: Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000321-41 Sponsor Protocol Number: ALENDROHNP2011 Start Date*: 2012-04-18
    Sponsor Name:FUNDACION HOSPITAL NACIONAL DE PARAPLEJICOS PARA LA INVESTIGACIÓN Y LA INTEGRACIÓN
    Full Title: PREVENTIVE TREATMENT OF BONE MASS LOSS WITH ALENDRONATE AND CALCIFEDIOL IN PATIENTS WITH ACUTE SPINAL CORD INJURY
    Medical condition: Preventing loss of bone density in patients with spinal cord injury of traumatic etiology complete during the first year of evolution of the lesion.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10041543 Spinal cord and nerve root disorders HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005081-37 Sponsor Protocol Number: 20050141 Start Date*: 2006-06-12
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Double-Blind Study to Compare the Efficacy of Treatment with Denosumab versus Alendronate Sodium in Postmenopausal Women with Low Bone Mineral Density
    Medical condition: Postmenopausal osteoporosis /osteopenia
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed) DE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-000849-19 Sponsor Protocol Number: 20050234 Start Date*: 2006-10-27
    Sponsor Name:Amgen Inc
    Full Title: A Randomized Study to Evaluate Safety and Efficacy of Transitioning Therapy From Alendronate to Denosumab (AMG 162) in Postmenopausal Women with Low Bone Mineral Density
    Medical condition: Postmenopausal Osteoporosis/osteopenia
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: EE (Completed) PT (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-010587-42 Sponsor Protocol Number: 20080099 Start Date*: 2009-09-17
    Sponsor Name:Amgen Inc
    Full Title: A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Monthly Actonel® Therapies in Postmenopausal Women Transitioned from Weekly or Daily Alendronate Therapy.
    Medical condition: Postmenopausal osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed) GB (Completed) PT (Completed) DE (Completed) FR (Completed) AT (Completed) IT (Completed) IE (Completed) ES (Completed) GR (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-014729-18 Sponsor Protocol Number: 5442-012-00 Start Date*: 2009-11-30
    Sponsor Name:Merck & Co., Inc.
    Full Title: “Un Ensayo de Fase IIb, Aleatorizado, Doble Ciego, Controlado con Placebo y Comparador Activo, de Determinación del Rango de Dosis para Evaluar los Efectos de MK-5442 en la Densidad Mineral Ósea ...
    Medical condition: Osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    9 10031285 Osteoporosis postmenopausal LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) GB (Completed) CZ (Completed) DK (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-024150-10 Sponsor Protocol Number: OPO-ALD-CHF-301 Start Date*: 2011-08-04
    Sponsor Name:Teva Pharmaceutical Industries Ltd.
    Full Title: A-15 week, double-blind, randomized, active-controlled, multicenter study to evaluate the efficacy and safety of Alendronate plus Vitamin D3 in women with osteoporosis
    Medical condition: Treatment of postmenopausal osteoporosis in patients at risk of vitamin D insufficiency.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2004-002317-37 Sponsor Protocol Number: HMR4003B/4034 Start Date*: 2004-11-18
    Sponsor Name:Aventis Inc.
    Full Title: OPEN-LABEL STUDY TO DETERMINE HOW PRIOR THERAPY WITH ALENDRONATE OR RISEDRONATE IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS INFLUENCES THE CLINICAL EFFECTIVENESS OF TERIPARATIDE
    Medical condition: Post-menopausal woman with 1 or more prevalent osteoporotic fractures and a BMD (spine or hip) of < -2.5 (see protocol amendment 2).
    Disease: Version SOC Term Classification Code Term Level
    7.0 10031285 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 06:40:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA